Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 3
2000 2
2001 6
2002 4
2003 4
2004 3
2005 3
2006 2
2007 1
2008 1
2009 3
2010 2
2011 3
2012 2
2013 4
2014 5
2015 4
2016 3
2017 7
2018 5
2019 6
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Results by year
Filters applied: . Clear all
Page 1
Innovative therapies for neovascular age-related macular degeneration.
Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU. Al-Khersan H, et al. Expert Opin Pharmacother. 2019 Oct;20(15):1879-1891. doi: 10.1080/14656566.2019.1636031. Epub 2019 Jul 12. Expert Opin Pharmacother. 2019. PMID: 31298960 Review.
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic t …
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outc …
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. CATT Research Group, et al. N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28. N Engl J Med. 2011. PMID: 21526923 Free PMC article. Clinical Trial.
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. ...
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneratio
Gene therapy for age-related macular degeneration.
Moore NA, Bracha P, Hussain RM, Morral N, Ciulla TA. Moore NA, et al. Expert Opin Biol Ther. 2017 Oct;17(10):1235-1244. doi: 10.1080/14712598.2017.1356817. Epub 2017 Jul 20. Expert Opin Biol Ther. 2017. PMID: 28726562 Review.
In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with 're …
In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor ( …
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM, Ciulla TA. Hussain RM, et al. Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246. doi: 10.1080/14728214.2017.1362390. Epub 2017 Aug 4. Expert Opin Emerg Drugs. 2017. PMID: 28756707 Review.
Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. ...
Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include lo …
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1. Ophthalmology. 2012. PMID: 22555112 Free PMC article. Clinical Trial.
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial. INTERVENTIONS: At enrollment, patients were assigned to 4 treatment groups defined by drug (r …
PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneratio
Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E, Ciulla TA, Hussain RM, Dugel PU. Kassa E, et al. Expert Opin Biol Ther. 2019 Apr;19(4):335-342. doi: 10.1080/14712598.2019.1575358. Epub 2019 Feb 11. Expert Opin Biol Ther. 2019. PMID: 30686077 Review.
INTRODUCTION: Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy (STGD1) result in vision loss due to progressive atrophy of the macula and lack of effective treatments. ...
INTRODUCTION: Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy (STGD1) result in vision loss due to progres …
Stargardt macular dystrophy and evolving therapies.
Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL. Hussain RM, et al. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. doi: 10.1080/14712598.2018.1513486. Epub 2018 Sep 10. Expert Opin Biol Ther. 2018. PMID: 30129371 Review.
INTRODUCTION: Stargardt macular dystrophy (STGD1) is a hereditary retinal degeneration that lacks effective treatment options. Gene therapy, stem cell therapy, and pharmacotherapy with visual cycle modulators (VCMs) and complement inhibitors are discussed as potential trea …
INTRODUCTION: Stargardt macular dystrophy (STGD1) is a hereditary retinal degeneration that lacks effective treatment options. Gene t …
Gene therapy for inherited retinal and optic nerve degenerations.
Moore NA, Morral N, Ciulla TA, Bracha P. Moore NA, et al. Expert Opin Biol Ther. 2018 Jan;18(1):37-49. doi: 10.1080/14712598.2018.1389886. Epub 2017 Oct 23. Expert Opin Biol Ther. 2018. PMID: 29057663 Review.
INTRODUCTION: The eye is a target for investigational gene therapy due to the monogenic nature of many inherited retinal and optic nerve degenerations (IRD), its accessibility, tight blood-ocular barrier, the ability to non-invasively monitor for functional and anatomic ou …
INTRODUCTION: The eye is a target for investigational gene therapy due to the monogenic nature of many inherited retinal and optic nerve …
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Hussain RM, et al. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Expert Opin Investig Drugs. 2019. PMID: 31513439 Review.
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Activation of Tie-2 receptor via Ang-1 maintains vascular stability to limit exudation. ...
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Brown DM, et al. Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018. Ophthalmology. 2009. PMID: 19118696 Clinical Trial.
OBJECTIVE: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photod …
OBJECTIVE: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly …
72 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page